Zacks: Twist Bioscience Corp (TWST) Given Consensus Recommendation of “Buy” by Brokerages

Twist Bioscience Corp (NASDAQ:TWST) has been assigned an average broker rating score of 1.67 (Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation and two have issued a strong buy recommendation on the company.

Analysts have set a 12 month consensus target price of $28.50 for the company and are forecasting that the company will post ($1.04) EPS for the current quarter, according to Zacks. Zacks has also given Twist Bioscience an industry rank of 77 out of 255 based on the ratings given to related companies.

Separately, Zacks Investment Research raised Twist Bioscience from a “sell” rating to a “hold” rating in a report on Wednesday, March 20th.

Shares of NASDAQ TWST traded up $1.38 during trading on Friday, reaching $25.04. The stock had a trading volume of 2,751 shares, compared to its average volume of 88,041. Twist Bioscience has a one year low of $12.38 and a one year high of $34.46. The company has a current ratio of 7.72, a quick ratio of 7.43 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $866.04 million and a price-to-earnings ratio of -0.98.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Tuesday, April 30th. The company reported ($0.93) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.03) by $0.10. The firm had revenue of $13.56 million during the quarter, compared to the consensus estimate of $11.88 million. As a group, equities analysts predict that Twist Bioscience will post -4.18 earnings per share for the current year.

Hedge funds have recently added to or reduced their stakes in the stock. FMR LLC acquired a new position in Twist Bioscience during the fourth quarter valued at approximately $26,090,000. Apoletto Ltd acquired a new position in shares of Twist Bioscience during the fourth quarter worth $10,503,000. BlackRock Inc. acquired a new position in shares of Twist Bioscience during the fourth quarter worth $7,782,000. Intellectus Partners LLC acquired a new position in shares of Twist Bioscience during the fourth quarter worth $4,076,000. Finally, Massachusetts Financial Services Co. MA acquired a new position in shares of Twist Bioscience during the fourth quarter worth $5,068,000. 22.74% of the stock is owned by hedge funds and other institutional investors.

About Twist Bioscience

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Further Reading: How are dividend achievers different from dividend aristocrats?

Get a free copy of the Zacks research report on Twist Bioscience (TWST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.